There are several novel therapeutic approaches in the clinical development of the treatment of metastatic prostate cancer: inhibition of androgen receptor signaling, immune-based treatments, antibody–drug conjugates, epigenetic therapies, and targeting radioligand emitters, among others (see Table 2). This evidence concerns the gene AR and metastatic prostate carcinoma.